Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Azurity gains access to Slayback's pipeline including, Precedex (dexmedetomidine hydrochloride), an alpha2-adrenergic agonist with sedative properties used for short-term intravenous sedation.
Lead Product(s): Dexmedetomidine Hydrochloride
Therapeutic Area: Neurology Product Name: Precedex-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Slayback Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 27, 2023
Details:
KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension) is a medication indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill adult patients.
Lead Product(s): Omeprazole,Sodium Bicarbonate
Therapeutic Area: Gastroenterology Product Name: Konvomep
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Brand Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Konvomep™ (omeprazole and sodium bicarbonate for oral suspension) is approved for the treatment of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill patients.
Lead Product(s): Omeprazole,Sodium Bicarbonate
Therapeutic Area: Gastroenterology Product Name: Konvomep
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2022
Details:
Slayback’s Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify® in U.S. Lumify® is an over-the-counter (OTC) eyedrop that can be used to relieve redness of the eye due to minor eye irritations.
Lead Product(s): Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimonidine Tartrate-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 29, 2022
Details:
Lumify® is an over-the-counter (OTC) eyedrop having Brimonidine Tartrate that can be used to relieve redness of the eye due to minor eye irritations. The agreement also provides Dr. Reddy’s exclusive rights to the product outside the U.S.
Lead Product(s): Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimonidine Tartrate-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 29, 2022
Details:
ZONISADE is first and only zonisamide formulation for oral liquid administration to be approved by FDA, as an adjunctive therapy for the treatment of partial seizures in adults and pediatric patients aged 16 years and older with epilepsy.
Lead Product(s): Zonisamide
Therapeutic Area: Neurology Product Name: Zonisade
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Details:
Zonisade is the first and only zonisamide formulation for oral liquid administration to be approved by the US Food and Drug Administration as an adjunctive therapy for the treatment of partial seizures in adults and paediatric patients aged 16 years and older with epilepsy.
Lead Product(s): Zonisamide
Therapeutic Area: Neurology Product Name: Zonisade
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Eton Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Details:
U.S.FDA has approved Abbreviated New Drug Application for Merzee (Slayback Pharma), an AB-rated generic equivalent of Taytulla® (Allergan), an estrogen/progestin combination oral contraceptive indicated for use by women to prevent pregnancy.
Lead Product(s): Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Merzee
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lupin Ltd
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
Partnering with leading engineered cell therapy developers is a key component of Arbor’s strategy to broaden the potential of CRISPR discovery engine beyond the wholly-owned in vivo genetic medicine approaches for the benefit of even more patients.
Lead Product(s): Ex-vivo Engineered Cell Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: EdiGene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 08, 2022
Details:
The combined company, operating as Azurity, will have a portfolio of products serving the unmet needs of patients in the cardiovascular, central nervous system, endocrinological, gastrointestinal, and institutional markets with many products like Epaned.
Lead Product(s): Enalapril Maleate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Epaned
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Azurity
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 24, 2021